New pill could shrink abnormal vessels in rare childhood disorders
Disease control
Not yet recruiting
This Phase 3 trial tests an oral drug called KP-001 in 150 people aged 2 and older with venous malformations, lymphatic malformations, or KTS/CLOVES syndrome. Participants receive either KP-001 or a placebo for 24 weeks, then everyone gets the drug for another 28 weeks. The goal …
Phase: PHASE3 • Sponsor: Kaken Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC